The major thrust of this study is to identify new germline polymorphisms in micro-RNAs (miRs) that are associated with increased risk of developing lung cancer (LC) or provide LC prognostic information. Such loci will be important in early cancer detection and patient management. In addition, we want to determine if miRs provide a blood biomarker for LC detection and if certain miR biomarkers also play a functional role in LC pathogenesis. miRNAs are a class of small non-coding endogenous RNAs capable of regulating an estimated third of human genes. miRNAs can function as oncogenes or tumor suppressor genes depending on the cellular context. In cancer, dysregulation of tumor suppressive or oncogenic miRNAs could have profound effects on various cellular processes including proliferation, differentiation, and cell death. miRNA relevant genomic variations may have regulatory effects on gene expression and cellular processing by altering gene splicing, modulating miRNA-target interaction, and disrupting miRNA biogenesis. However, no studies have systematically screened and validated SNPs in miRNA pathways as modulators of LC risk and outcomes. One of the added advantages of miRNA and miR pathway targeted study of SNPs (miR-SNPs) is that most miR-SNPs are not covered by current GWAS chips. Therefore, we propose to conduct a systematic analysis of SNPs in miRs and miR pathway(s) as susceptibility factors for NSCLC risk and clinical outcome, incorporating germline miR-SNP genotyping, somatic miRNA profiling, circulating miRNA detection, and functional characterization. This proposal builds upon a rich specimen repository, well annotated with comprehensive epidemiologic, clinical and genetic data, from one of the largest LC studies in the U. S., MD Anderson LC Study, along with the Harvard LC study. The four specific aims are:
Aim 1) To screen and validate a custom array of ~6,000 miR-SNPs as predictors of NSCLC risk using a three-stage design (discovery, internal and external validation) in a total of 4,800 Caucasian cases and 4,800 matched controls, as well as 1,600 pairs of African American cases and controls;
Aim 2) To screen and validate the above 6,000 miR-SNPs as predictors of NSCLC recurrence in the subset of surgically resected early stage NSCLC patients using a similar three-stage design;
Aim 3) To identify circulating miRNAs as predictors for recurrence in early stage NSCLC using a testing and validation design;
Aim 4) To determine the functional impact on lung cancer of significant miR-SNPs and miRNAs identified from the above aims.

Public Health Relevance

Primary lung cancer (LC) is the most common cancer and the leading cause of cancer death and non-small cell lung cancer (NSCLC) accounts for over 80% of LC cases. This project aims to identify genetic miR variants for NSCLC risk and recurrence and circulating miR biomarkers for recurrence in early stage patients. The identified biomarkers may be incorporated into risk prediction models to improve risk stratification for cost-effective surveillance, screening, detection, and personalized management of early stage lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-16A1
Application #
8747046
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
1996-09-30
Project End
2019-08-31
Budget Start
2014-09-23
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$424,704
Indirect Cost
$85,103
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Guo, Hou-Fu; Tsai, Chi-Lin; Terajima, Masahiko et al. (2018) Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nat Commun 9:512
Meraz, Ismail M; Majidi, Mourad; Cao, Xiaobo et al. (2018) TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunol Res 6:163-177
Zhang, Liren; Lin, Jing; Ye, Yuanqing et al. (2018) Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther 103:1061-1073
Bayo, Juan; Tran, Tram Anh; Wang, Lei et al. (2018) Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks. Cell Rep 25:1040-1050.e5
Ludlow, Andrew T; Wong, Mandy Sze; Robin, Jerome D et al. (2018) NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun 9:3112
Chen, Limo; Diao, Lixia; Yang, Yongbin et al. (2018) CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8:1156-1175
Mender, Ilgen; LaRanger, Ryan; Luitel, Krishna et al. (2018) Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 20:826-837
Gong, Ke; Guo, Gao; Gerber, David E et al. (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500-2518
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640

Showing the most recent 10 out of 1059 publications